Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
- Concurrent Use Restrictions Lifted for 3 DPP-4 Inhibitor Products
May 27, 2014
- Chugai Concludes Deal with Roche for Chugai’s Antibody Engineering Technologies
May 27, 2014
- Daiichi Sankyo, US Research Institute to Collaborate in Developing Cardiovascular-Metabolic Disease Treatments
May 26, 2014
- 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
- Astellas Launches Anticancer Drug Xtandi Capsules in Japan
May 26, 2014
- Three Companies Including DSP Jointly Invest 845 Million Yen in Create Vaccine
May 26, 2014
- Teikoku Seiyaku Licenses Antiallergic Treatment from Uriach of Spain
May 26, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
- Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
- 5 of 17 Pharmacy Chains Settle April-June Delivery Prices via Qol-Led Open Tender
May 23, 2014
- Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
- JPMA Code Committee to Discuss Actions against Kyowa Kirin, Novartis over Improper Involvement in Clinical Trials
May 22, 2014
- Takeda’s UC, CD Treatment Entyvio Approved in US
May 22, 2014
- EPS Did Nothing Wrong in Data Verifications for VART Study Probe: Pres.
May 21, 2014
- AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
- Towa Wins Japan’s 1st Approval for Viagra Generic
May 21, 2014
- Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
- Medipal Holdings Sets 2,253 Billion Yen Goal for FY2016 Ethical Drug Wholesaling Sales
May 20, 2014
- Daiichi Sankyo to Revise Its Midterm Business Plan Due to Transfer of Ranbaxy
May 20, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…